Oppenheimer analyst Jay Olson reiterated an Outperform rating and $140.00 price target on Nektar Therapeutics (NASDAQ: NKTR).The analyst commented: "This ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE